Trial · NCT02409355
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
NCT02409355, Phase 3, Terminated, Hoffmann-La Roche; results first posted 2018-11-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111). Trials, record NCT02409355. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02409355
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
- NCT number
- NCT02409355
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 8 participants, actual
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab, Carboplatin, Cisplatin, Gemcitabine
- First posted
- 2015-04-06
- Last updated
- 2019-02-15
- Other registries' IDs
- eudract:2014-003106-33
- Results first posted
- 2018-11-14
- Limitations and caveats
- The study was closed due to low enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Baseline up to death or disease progression, whichever occurs first (up to approximately 2.5 years) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Baseline up to death or disease progression, whichever occurs first (up to approximately 2.5 years) | The study was closed due to low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study. The planned outcome measures of this study are no longer applicable. The outcome measures were removed in the last protocol version. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Atezolizumab | 4 | |
| Overall Study | STARTED | Gemcitabine + Cisplatin/Carboplatin | 4 | |
| Overall Study | COMPLETED | Atezolizumab | 0 | |
| Overall Study | COMPLETED | Gemcitabine + Cisplatin/Carboplatin | 0 | |
| Overall Study | NOT COMPLETED | Atezolizumab | 4 | |
| Overall Study | NOT COMPLETED | Gemcitabine + Cisplatin/Carboplatin | 4 |
Source ClinicalTrials.gov
Adverse events124
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Atezolizumab | 1 | 4 | 1 |
| other | ANAEMIA | Blood and lymphatic system disorders | Gemcitabine + Cisplatin/Carboplatin | 3 | 4 | 3 |
| other | GRANULOCYTOPENIA | Blood and lymphatic system disorders | Atezolizumab | 0 | 4 | 0 |
| other | GRANULOCYTOPENIA | Blood and lymphatic system disorders | Gemcitabine + Cisplatin/Carboplatin | 1 | 4 | 1 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Atezolizumab | 0 | 4 | 0 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Gemcitabine + Cisplatin/Carboplatin | 1 | 4 | 1 |
| other | CONSTIPATION | Gastrointestinal disorders | Atezolizumab | 1 | 4 | 1 |
| other | CONSTIPATION | Gastrointestinal disorders | Gemcitabine + Cisplatin/Carboplatin | 0 | 4 | 0 |
| other | DIARRHOEA | Gastrointestinal disorders | Atezolizumab | 1 | 4 | 1 |
| other | DIARRHOEA | Gastrointestinal disorders | Gemcitabine + Cisplatin/Carboplatin | 1 | 4 | 1 |
1 to 10 of 124Source ClinicalTrials.gov
See all 124 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Atezolizumab | 1 | 4 |
| Total, all-cause mortality | Gemcitabine + Cisplatin/Carboplatin | 1 | 4 |
| Total, other adverse events | Atezolizumab | 4 | 4 |
| Total, other adverse events | Gemcitabine + Cisplatin/Carboplatin | 3 | 4 |
| Total, serious adverse events | Atezolizumab | 1 | 4 |
| Total, serious adverse events | Gemcitabine + Cisplatin/Carboplatin | 1 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Atezolizumab vs Gemcitabine + Cisplatin/Carboplatin: deaths from any cause | Trial comparisons |
| Atezolizumab vs Gemcitabine + Cisplatin/Carboplatin: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02409355
GET https://conductscience.org/api/trials/v1/NCT02409355/events?page=2